申请人:MERCK SHARP & DOHME CORP.
                            
                            
                                公开号:US20170008899A1
                            
                            
                                公开(公告)日:2017-01-12
                            
                            Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.